-
Mashup Score: 12Biological Heterogeneity in Diffuse Large B-cell Lymphoma - 5 month(s) ago
Diffuse large B-cell lymphoma (DLBCL) is heterogeneous both in clinical outcomes and the underlying disease biology. Over the last two decades, severa…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis - 7 month(s) ago
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis https://t.co/0oATLv4osP This is fascinating.
-
-
Mashup Score: 0OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA... by Maurizio Martelli - 12 month(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-C... by Maurizio Martelli EHA Library; Jun 08 2023; 387801 https://t.co/7Xkyk8QiQL
-
-
Mashup Score: 0FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD... by Hermann Einsele - 12 month(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
EHA Library - The official digital education library of European Hematology Association (EHA) https://t.co/KJnNt6AZSn
-
-
Mashup Score: 0Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study - 1 year(s) ago
Key Points. Liso-cel significantly improved EFS, CR rate, and PFS vs chemotherapy ± ASCT as a second-line treatment for LBCL.Liso-cel was well tolerated as a se
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study https://t.co/u9Eh8twq72
-
-
Mashup Score: 1Outcomes after biochemical or clinical progression in patients with multiple myeloma - 1 year(s) ago
Key Points. Patients with MM after CP have inferior survival compared with patients with MM after BP.Patients with MM tend to present symptoms at relapse simila
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Outcomes after biochemical or clinical progression in patients with multiple myeloma https://t.co/F9rZEGe9Xl
-
-
Mashup Score: 2
We are pleased to add this typescript, Inappropriate use of statistical power by Raphael Fraser to the BONE MARROW TRANSPLANTATION Statistics Series. The authour discusses how we sometimes misuse statistical analyses after a study is completed and analyzed to explain the results. The most egregious example is post hoc power calculations. When the conclusion of an observational study or clinical…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Inappropriate use of statistical power | Bone Marrow Transplantation Fantastic Editorial. https://t.co/So2VSKVi5b
-
-
Mashup Score: 0
Complementing the recently published Blood articles outlining the 2022 International Consensus Classifications for hematological malignancies (Vol. 140, Issue 1
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Genomic profiling for clinical decision making in lymphoid neoplasms | Blood | American Society of Hematology https://t.co/5QI9CSESYQ
-
-
Mashup Score: 0Allogeneic natural killer cell therapy - 1 year(s) ago
Interest in adoptive cell therapy for treating cancer is exploding due to early clinical successes of autologous chimeric antigen receptor (CAR) T lymphocytes.
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Allogeneic natural killer cell therapy https://t.co/CIPQJD5gsJ
-
-
Mashup Score: 0Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia - 1 year(s) ago
Complementing the recently published Blood articles outlining the 2022 International Consensus Classifications for hematological malignancies (Vol. 140, Issue 1
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia https://t.co/KQVg5ASBF6
-
The perfect figure exist! The Dark Side of The Moon representation of DLBCL genomic classification. Kudos for the authors. https://t.co/7RoeQMAz9n https://t.co/kFFNW9rf59